Venture Products unveils new line of yoga products
FAIRFIELD, N.J. — Venture Products earlier this week announced a new line of yoga and fitness accessories under its Shock Athletic brand name. These products complement Venture’s existing lineup of yoga mats.
Available in various fashionable colors, the new fitness accessories lineup — being launched at select Sears and Kmart locations nationwide — includes yoga blocks, straps, mat carriers, nonslip socks, towel mats, stability balls, exercise bands and toning tubes.
"Yoga accessories are essential additions for any level of yoga workout,” stated Venture Products partner Steve Fischer. “Each item — from the blocks to the straps — works as an aid to help produce more precise yoga poses and, in turn, a safer workout.”
The entire Shock Athletic line is infused during the manufacturing process with Microban antimicrobial zinc technology, which inhibits the growth of stain- and odor-causing bacteria, mold and mildew, and is effective for the life of the product. Microban is a registered trademark of Microban Products Company.
Organix-South launches TheraVeda Immune Support
BOWLING GREEN, Fla. — Organix-South earlier this week launched TheraVeda Immune Support, an herbal blend of turmeric, neem and ginger, plus ashwagandha, guduchi and holy basil to support overall strength and stamina.
The TheraVeda line, which includes seven condition-specific formulas, was developed by Organix-South in partnership with Shrikrishna Phadke, Ayurvedic practitioner and teaching physician.
According to Organix- South founder Autumn Blum, “TheraVeda Immune Support is like an herbal multivitamin with herbs that have been traditionally used to fortify and protect our overall well-being and address the occasional seasonal imbalance. Our Immune Support is a first-reach formula to help build a strong foundation to better respond to stressors, calm the nervous system and promote overall immune intelligence.”
Watson files for approval of generic painkiller
PARSIPPANY, N.J. — Watson Pharmaceuticals is looking to become the first to market a generic version of a painkiller made by Pfizer, the drug maker said Friday.
Watson said it filed a regulatory approval application with the Food and Drug Administration for morphine sulfate and naltrexone hydrochloride extended-release capsules in the 30-mg/1.2-mg, 50-mg/2-mg, 60-mg/2.4-mg, 80-mg/3.2-mg and 100-mg/4-mg strengths. The drug is a generic version of Embeda, made by Pfizer subsidiary King Pharmaceuticals.
Pfizer, King and Alpharma Pharmaceuticals filed a patent infringement suit against Watson Thursday, alleging that Watson’s product violates three patents covering Embeda. Filed under the provisions of the Hatch-Waxman Act of 1984 — the law that created an abbreviated approval pathway for generic pharmaceuticals — the suit puts a stay of final FDA approval of the drug for 30 months, or until the companies settle.
Embeda had sales of about $42 million during the 12-month period ended in August, according to IMS Health.